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http://dx.doi.org/10.1016/j.ccr.2014.07.007SUMMARYNumerous oncogenic mutations occur within the BRAF kinase domain (BRAFKD). Here we show that stable
BRAF-MEK1 complexes are enriched in BRAFWT and KRAS mutant (MT) cells but not in BRAFMT cells. The
crystal structure of the BRAFKD in a complexwithMEK1 reveals a face-to-face dimer sensitive toMEK1 phos-
phorylation but insensitive to BRAF dimerization. Structure-guided studies reveal that oncogenic BRAF
mutations function by bypassing the requirement for BRAF dimerization for activity or weakening the inter-
action with MEK1. Finally, we show that conformation-specific BRAF inhibitors can sequester a dormant
BRAF-MEK1 complex resulting in pathway inhibition. Taken together, these findings reveal a regulatory
role for BRAF in theMAPK pathway independent of its kinase activity but dependent on interaction withMEK.INTRODUCTION
The Ras-RAF-MEK-ERK signaling pathway (mitogen-activated
protein kinase [MAPK] pathway) plays a major role in cellular
growth, differentiation, survival, and senescence (Wellbrock
et al., 2004). Not surprisingly, this pathway is frequently dysregu-
lated in human cancers with many tumors harboring RAS or RAF
mutations resulting in constitutive activation of the pathway
(Roberts and Der, 2007; Schubbert et al., 2007). The three RAF
isoforms in humans, ARAF, BRAF, and CRAF, have distinct
mechanisms of activation (Baljuls et al., 2007; Galabova-Kovacs
et al., 2006; Hu et al., 2013; Wimmer and Baccarini, 2010), with
BRAF being less regulated overall (Chong et al., 2001). Despite
these differences, spatial activation of RAF by RAS-guanosine
triphosphate (GTP) remains a common regulatory step for
normal MAPK pathway activation. The association of RAS-GTPSignificance
The MAPK pathway is frequently activated in human cancers.
activation that can be bypassed by oncogenic mutations in th
forms a high affinity complex with MEK1 that is independent o
BRAF-MEK1 complexes are enriched in the cytosol of BRAFW
activation through either EGF stimulation or oncogenic BRAF
of MEK1 by BRAF is not the rate-limiting step in pathway activ
found implications for both our fundamental understanding of
402 Cancer Cell 26, 402–413, September 8, 2014 ª2014 Elsevier Incwith the Ras binding domain of RAF at the plasma membrane
promotes homodimerization or heterodimerization of RAF proto-
mers (Goetz et al., 2003; Kolch, 2000; Weber et al., 2001). This
association, in addition to CRAF phosphorylation, results in an
activating conformational change in the RAF kinase domain
leading to phosphorylation of MEK on S218 and S222 (Rajaku-
lendran et al., 2009; Rushworth et al., 2006). Activated MEK in
turn phosphorylates the terminal kinase ERK.
Kinase suppressor of Ras (KSR) is a scaffolding protein that
can enhance the duration and amplitude of MAPK signaling
(Kornfeld et al., 1995; Sundaram and Han, 1995; Therrien et al.,
1995) through assembly of activating complexes involving
BRAF, MEK, and ERK (Clape´ron and Therrien, 2007; Kolch,
2005; Nguyen et al., 2002; Roy et al., 2002). KSR is homologous
to RAF kinases but lacks both an important catalytic lysine within
the kinase domain and the ability to bind RAS directly. While theHere we define a regulatory mechanism for MAPK pathway
e BRAF kinase domain. Our studies demonstrate that BRAF
f BRAF dimerization but sensitive to MEK1 phosphorylation.
T and KRASMT tumor cells and disassociate upon pathway
mutations. Importantly, our work illustrates that recognition
ation, but rather BRAF-CRAF dimerization is. This has pro-
MAPK biology and therapeutic design.
.
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Kinase-Independent Role for BRAF in MAPK Signalingphysiological relevance of KSR catalytic activity remains contro-
versial (Brennan et al., 2011; Michaud et al., 1997), the ability of
KSR to activate RAF through KSR-RAF dimers is well estab-
lished (McKay et al., 2009; Rajakulendran et al., 2009). Thus,
KSR plays an operative role in RAF activation in addition to regu-
lating spatial and temporal dynamics of MAPK signaling. KSR,
like RAF, binds MEK (Brennan et al., 2011). The crystal structure
of MEK1 bound to the kinase domain of KSR2 reveals that MEK1
residues S218 and S222 lie at the heterodimer interface and are
masked by KSR2 such that they are inaccessible for phosphor-
ylation by RAF (Brennan et al., 2011). Thus, whether KSR or RAF
is directly bound toMEK in vivo impacts themechanism of signal
transduction.
The precisemechanism of pathway activation in the context of
cancer provides an additional layer of complexity and is depen-
dent on the underlying genetic mutation. For example, the kinase
activating BRAFV600E mutation, found in more than 60% of mel-
anomas, promotes MAPK pathway signaling independent of
RAS activation (Davies et al., 2002; Wan et al., 2004). While
spatial activation and dimerization of RAF kinases are central
regulatory mechanisms in BRAFWT and KRAS mutant (MT) con-
texts (Garnett et al., 2005; Rushworth et al., 2006; Weber et al.,
2001), BRAFV600E cell lines are insensitive to these regulatory
events (Ro¨ring et al., 2012). In contrast, nonactivating oncogenic
mutations in the BRAF kinase domain promote pathway sig-
naling through CRAF activation (Wan et al., 2004). BRAFP-loop
mutations activate the pathway through enhanced dimerization
with CRAF independent of RAS but requiring CRAF activation
loop phosphorylation and interaction with 14-3-3 (Garnett
et al., 2005). Interestingly, unlike the activating BRAFV600E mu-
tation that is mutually exclusive with respect to RAS mutations,
tumor cell lines harboring BRAFP loop mutations may also have
activating RAS mutations (i.e., MDA-MB-231), suggesting
that RAS may play a role in enhancing pathway activation in
BRAFP loop tumors. Similarly, in vivo studies with the kinase
dead BRAF mutant BRAFD594V illustrate that active RAS is
required for BRAFD594V induced melanoma in mice (Heidorn
et al., 2010). Therefore, in the context of nonactivating BRAFmu-
tations, additional mechanisms are required to drive dimerization
with CRAF and pathway activation, including but not limited to
interactions with RAS and 14-3-3.
The effects of BRAF inhibitors are similarly complex. ATP
competitive inhibitors of BRAF such as vemurafenib (PLX4032)
have shown significant antitumor activity in the clinic for treat-
ment of metastatic melanomas harboring the BRAFV600E muta-
tion (Pe´rez-Lorenzo and Zheng, 2012; Ribas and Flaherty,
2011). However, in BRAFWT cells, BRAF inhibitors paradoxically
activate the MAPK pathway by inducing dimerization of BRAF
with CRAF in a RAS-GTP-dependentmanner. The proposedmo-
lecular mechanism of RAF activation appears to be due to inhib-
itor binding to one protomer of RAF (i.e., BRAF) and inducing
dimerization with a second RAF protomer (i.e., CRAF), which re-
sults in activation of the pathway through increased CRAF kinase
activity (Hatzivassiliou et al., 2010; Heidorn et al., 2010; Poulika-
kos et al., 2010). With high concentration of inhibitor, both BRAF
and CRAF protomers are bound to the inhibitor and signaling is
blocked. It has also been reported that certain BRAF inhibitors
can induce KSR-RAF dimers (Hu et al., 2011; McKay et al.,
2011). In this context inhibitor bound BRAF competes withCaCRAF for binding to KSR, suggesting that BRAF inhibitors
can elicit allosteric effects on both kinase signaling as well as
scaffolding components in the MAPK pathway (McKay et al.,
2011). Further, while most type I BRAF inhibitors paradoxically
prime the pathway in BRAFWT cells, not all type I BRAF inhibitors
induce BRAF-CRAF or RAF-KSR dimers as this effect is confor-
mation specific, requiring the active, closed conformation of the
BRAFKD (Hatzivassiliou et al., 2010; Lavoie et al., 2013; McKay
et al., 2011). Hence, conformation-specific paradoxical RAF
activation underscores the importance of understanding the
noncatalytic functions of this family of kinases.
Recently, specific classes of allosteric MEK inhibitors were re-
ported to sequester a RAF-MEK protein complex, which resulted
in greater efficacy in KRASMT cancer models (Hatzivassiliou
et al., 2013; Ishii et al., 2013). This class of MEK inhibitor pre-
vents RAF from phosphorylating MEK at S218 and S222 and
therefore not only blocks MEK kinase activity but also RAF-
dependent phosphorylation of MEK. Interestingly, these inhibi-
tors cannot sequester a BRAFV600E-MEK protein complex and
are not as effective in a BRAFV600E background (Hatzivassiliou
et al., 2013). This raises the question whether preformed RAF-
MEK complexes exist prior to MAPK pathway activation and if
the specific genetic context determines the types of signaling
complexes present basally in cells.
RESULTS
Cytosolic BRAF-MEK1 Complexes Are Enriched in
BRAFWT and KRASMT Cells
We analyzed phosphorylation of MEK1 across a panel of
BRAFWT,BRAFMT, andKRASMT cell lines. In agreement with pre-
vious reports, we observe that phospho-MEK (pMEK) levels are
elevated in BRAFMT cell lines (BRAFV600E or BRAFP-loop) but are
dampened in BRAFWT and KRASMT cell lines (Figure 1A and Fig-
ure S1A available online). Coimmunoprecipitation (coIP) ofMEK1
with BRAF and CRAF revealed that endogenous BRAF-MEK1
complexes are enriched in multiple KRASMT and BRAFWT/
KRASWT cell lines where pMEK levels are low, but are signifi-
cantly less abundant in the BRAFV600E and BRAFP loop cell lines,
where pMEK levels are elevated (Figure 1A and Figure S1A).
Given the high degree of sequence identity between BRAF and
CRAF kinase domains (Figure S1B), we also observed CRAF-
MEK1 complexes in a small subset of cell lines (i.e., PATU,
Colo678). In order to ascertain the relative stoichiometry of this
complex, we conducted serial MEK1 coimmunodepeletion ex-
periments in HCT116 and HEK293 cell lines where basal pMEK
levels were low and BRAF-MEK1 complexes were present. As
seen in Figure S1C, even when all MEK1 and MEK1-BRAF com-
plexes are immunodepleted from cell lysates, free BRAF and
CRAF remain in the flow through, suggesting that not all of
BRAF is bound to MEK1 and that there is a dynamic equilibrium
between BRAF-MEK1 and free BRAF and CRAF in cell lines
where complexes are observed (Figure S1C). This result also
suggests that substrate recognition (i.e., recognition of MEK1
by RAF) is not a rate-limiting step in RAF-dependent MEK phos-
phorylation. Whereas catalytic activity of BRAF enhances pMEK
levels in BRAFV600E lines, increased formation of BRAF-CRAF
heterodimers and CRAF activation drive pathway activity in
BRAFP-loop cell lines, as indicated by coIP of CRAF with BRAFncer Cell 26, 402–413, September 8, 2014 ª2014 Elsevier Inc. 403
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Figure 1. Oncogenic Mutations of BRAF
Disrupt a Cytosolic BRAF-MEK1 Complex
(A) Immunoblot of whole cell lysates (WCL) and
immunoprecipitation (IP) of MEK1 of cell lines
harboring RAS/RAFWT (HELA, HEK293T),
KRASMT, BRAFV600E, or BRAFP-loop (BRAFG464E/V,
BRAFG466V). A375 (BRAFV600E) was included in
each panel to allow for direct comparison of pMEK
levels across cell lines. An asterisk (*) denotes cell
lines that contain an activating KRASMT.
(B) IP of CRAF followed by immunoblot analysis of
cell lines harboring BRAFP-loop (HEY1, MDA-MB-
231, H1666) compared to A375 (BRAFV600E) and
HCT116 (KRASMT) cell lines.
(C) IP of MEK1 followed by immunoblot analysis
from membrane and cytosolic fractionated cell ly-
sates of HCT116 (KRASMT), A375 (BRAFV600E), and
HEK293T (RAS/RAFWT) cells (top); 80% of the
membrane enriched fraction and cytosolic en-
riched fraction were used for IP. RHO-GDI and Ras
serve as cytosolic and membrane controls, res-
pectively (bottom).
(D) HEK293T cells stimulated with 100 ng/ml EGF
for the indicated times (min) followed by immuno-
blots of WCL or IP of BRAF.
See also Figure S1.
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Kinase-Independent Role for BRAF in MAPK Signalingand CRAF phosphorylation at S338 (pS338) (Figure 1B). As one
of the hallmarks of RAF activation is RAS-GTP-dependent mem-
brane localization, we assessed whether the BRAF-MEK1 com-
plex observed basally in KRASMT and BRAFWT cell lines resides
in the cytosol or membrane fraction. Subcellular fractionation
studies in cell lines harboring KRASMT (HCT116), BRAFV600E
(A375), or RAS/RAFWT (HEK293T) reveal that BRAF-MEK1 com-
plexes reside in the cytosol of HCT116 and HEK293T cell lines,
supporting the model where BRAF and CRAF are primarily cy-
tosolic until activated (Garnett et al., 2005; Marais et al., 1997)
(Figure 1C). Collectively, these data indicate that enrichment of
cytosolic BRAF-MEK1 complexes in BRAFWT and KRASMT cells
is coincident with decreased pMEK levels, suggesting that this
complex is quiescent and awaiting pathway activation. Pathway
activation following epidermal growth factor (EGF) stimulation of
HEK293 BRAFWT cells results in disruption of the BRAF-MEK1
complex and enhanced levels of phosphorylated MEK1 and
ERK1/2 followed by reemergence of the BRAF-MEK complex
at the longer time points when pMEK levels return to their basal
levels (Figure 1D). Hence, dissociation and formation of the
BRAF-MEK1 complex correlates with pathway activation, sug-
gesting that this complex is a regulatory component in MAPK
signaling.
In order to assess directly whether RAF dimerization is
required for interaction with MEK1 or RAS-GTP, we conducted
cotransfection experiments in HEK293 cells with mCherry-
tagged WT BRAF or BRAFR509H and Flag-tagged WT BRAF404 Cancer Cell 26, 402–413, September 8, 2014 ª2014 Elsevier Inc.with growth factor stimulation. As seen
in Figure S1D, pathway stimulation with
EGF at very early time points (5 min) pro-
motes BRAF association with RAS in a
BRAF-dimerization-dependent manner,
illustrating that BRAF dimerization isrequired for interaction with RAS-GTP. Notably, overexpression
studies do not capture the dynamic plasticity between BRAF and
MEK1 in response to EGF as observed with endogenous pro-
teins. Our cellular studies illustrate that BRAF and MEK form a
quiescent, cytosolic complex that can be activated upon
pathway stimulation through RAF dimerization.
Crystal Structure of BRAFwithMEK1Reveals a Face-to-
Face Kinase-Substrate Complex
To elucidate the molecular basis of the BRAF-MEK1 interaction,
we determined a 2.85 A˚ crystal structure of the complex of
human BRAFKD (residues 432–726) with its substrate DNMEK1
(MEK1 with N-terminal deletion, residues 62–393), ATP mimetic
AMPPCP (ACP), and G-573 (Choo et al., 2010), an ATP-uncom-
petitive inhibitor of MEK1 (Figure 2A; Table S1). This structure re-
vealed that BRAFKD and DNMEK1 form a stable tetramer in which
a central BRAFKD dimer interacts with twomolecules of DNMEK1.
BRAFKD and MEK1 form a face-to-face heterodimer with juxta-
posed ATP binding sites (Figure 2B). This face-to-face interac-
tion is analogous to the complex formed between p38 and its
substrate MAPK-activated protein kinase 2 (White et al., 2007).
The details of the BRAF-MEK1 and p38-MK2 interactions differ
considerably, indicating that variation in kinase-kinase inter-
actions is tolerated andmay have been exploited by evolutionary
forces to generate additional regulatorymechanisms. Although it
has been demonstrated that BRAF dimerization is important for




Figure 2. BRAF and MEK1 Form a Stable Tetramer that Is Mediated
through the BRAF Dimer Interface
(A) The heterotetramer formed by BRAFKD (cyan, blue) and DNMEK1 (pink, red).
(B)MEK1 (pink, red AS [activation segments]) andBRAFKD (cyan, blue AS) form
a face-to-face dimer. ACP (green) and G-573 (lime) are bound in the cleft
between the N lobe and C lobe of MEK1. BRAF phosphorylation sites in MEK1
(S218, S222: yellow) and residues in BRAFKD that can harbor oncogenic mu-
tations are highlighted (inactivating mutations G464 and G466: orange; acti-
vating mutations E585, V600, and K601: yellow).
(C) Close-up of the MEK1 active site and the BRAFKD-MEK1 interface shows
that the AS, aEF, and aG helices in the C lobes of both BRAF and MEK1
interact via a hydrophobic interface (gray spheres). G614 and I616 (side chain
depicted) from BRAF AS and S222 (in yellow) and V224 fromMEK1 AS interact
via intermolecular hydrogen bonds (3.2 A˚ each, shownwith dotted black lines).
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CaBRAF dimerization with monomeric BRAF (BRAFR509H) still
competent to bindMEK1with similarly high affinity as the dimeric
BRAFWT (Figures S2A and S2B) with KD values in the 40–60 nM
range. This is consistent with our transient transfection ex-
periments where both BRAFWT and the monomeric BRAFR509H
immunoprecipitate with MEK.
The BRAFKD-MEK1 interface is formed by both the b-rich N
lobes and the predominantly a-helical C lobes, yielding a high af-
finity interaction (KD 43 nM; Figure S2B) with critical contacts
between the activation segments (AS) of the two proteins (Fig-
ures 2B and 2C). The active conformation of the BRAF AS is sta-
bilized by an intramolecular salt bridge between R575, the
conserved ‘‘R’’ in the BRAF ‘‘HRD’’ motif, and E611 in BRAF (Fig-
ure 2C). E611 acts as a phosphomimic to stabilize the active
conformation of BRAF AS and aligns structurally with phosphor-
ylated threonine residues in the active conformation of kinases
such as T197 in PKCa (Protein Data Bank [PDB] code 1ATP).
Thus, R575 is not expected to interact with a phosphorylated
residue in the AS as is typical for the HRD motif, suggesting
that BRAF can adopt an active conformation in a complex with
MEK1 in the absence of phosphorylation of its activation
segment. Residues analogous to R575 and E611 are conserved
across the RAF family, indicating this is a shared feature of all
RAF family members.
In the complex described above, BRAFKD adopts an active-
like conformation of the aC helix and AS, whereas MEK1 is in
an inactive conformation (Figure 2B; Figure S2C). ACP and
Mg2+ are found in the MEK1 active site, while G-573 is bound
at the adjacent allosteric site between the N and C lobes (Figures
2B and 2C; Figure S2D). While G-573 and ACP are not necessary
for formation of a tetrameric or dimeric BRAFKD-MEK1 complex
in solution (Figures S2A and S2E), inclusion of G-573 stabilizes
the complex in a preactivation-like state through specific interac-
tions with the MEK1 activation loop. G-573 forms numerous in-
teractions with MEK1 including a hydrogen bond with the amide
backbone of S212 in the AS such that MEK1 residues S218 and
S222 are not accessible for phosphorylation by BRAF (Fig-
ure S2D) (Hatzivassiliou et al., 2013). In the absence of this in-
hibitor, the MEK1 activation loop is likely sufficiently flexible to
access the active site of BRAF without disruption of the rest of
the interface. Phosphorylation at S218 and S222 following incu-
bation of RAF and MEK1 with ATP may result in dissociation of
RAFKD-MEK1 complexes due to the steric and electrostatic ef-
fects of phosphorylation. Binding of a nucleotide analog alone
(AMP-PCP) in the absence of a MEK inhibitor has no effect on
complex formation (Figure S2E). However, these data do not
eliminate the possibility that MEK1 is released from BRAF and
then phosphorylated. To confirm that BRAF phosphorylation
does not significantly affect the interaction with MEK1, we con-
ducted mass spectrometric experiments where BRAF alone or
in a complex with MEK1 was incubated with or without ATP.
As observed in Figures S2F–S2M, purified recombinant BRAFKD
is constitutively phosphorylated at S446 and no significant
changes in BRAF phosphorylation are observed when in a com-
plex with MEK in the absence or presence of ATP. These data(D) Surface representation of MEK1 with BRAFKD, KSRKD, and MEK1 binding
surfaces highlighted in blue, yellow, and red, respectively.
See also Table S1 and Figure S2.
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Figure 3. Point Mutations at the BRAF-MEK1 Interface Disrupt
Dimer Formation and Have Functional Consequences
(A) Structure of the BRAF-MEK1 complex showing relative position of the
residues that upon mutation weaken or disrupt the BRAF-MEK1 complex.
(B) Immunoblot analysis ofWCL or IP of Flag-BRAF from lysates prepared from
HEC1ABRAF/ transfected for 24 hr with vectors expressing theWTBRAF or
the indicated BRAF mutants. Levels of MEK1 were analyzed after a short
exposure (short) and long exposure (long).
(C) Recombinant BRAFKD and MEK1 protein variants with indicated amino
acid substitutions at the BRAF-MEK1 interface are tested for dimer formation
by homogenous time-resolved fluorescence. Error bars indicate ±SD.
(D) In vitro cascade kinase assays using recombinant MEK1 protein variants
and recombinant BRAF and ERK.
Cancer Cell
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406 Cancer Cell 26, 402–413, September 8, 2014 ª2014 Elsevier Incindicate that the BRAF-MEK complex is sensitive to MEK phos-
phorylation at S218 and S222 but not to the BRAF phosphoryla-
tion state.
A comparison of our BRAFKD-MEK1 structure to the structure
of MEK1 in a complex with the kinase-like domain of KSR2
(KSR2KD) (Brennan et al., 2011) (Figure S2N) reveals overall
structural similarities. However, unlike the BRAF kinase domain,
the AS and aC helix of KSR are in an inactive conformation in a
complex with MEK (Figure S2O). Further, the KSRKD is rotated
25 relative to the BRAFKD, resulting in fewer interactions
with the N and C lobes of MEK (Figure S2N). The BRAFKD-
MEK1, KSR2-MEK1 (Brennan et al., 2011), and MEK1-MEK1
(Ohren et al., 2004) interactions all utilize a common conserved
surface on the C lobe of MEK1 (Figure 2D), indicating that MEK1
binding to BRAF, KSR, or another MEK1 molecule is mutually
exclusive. Further, given the high affinity BRAF-MEK1 complex
exists as a stable heterotetramer in solution while the MEK1-
MEK1 complex exists in a monomer-dimer equilibrium (Fig-
ure S2A), formation of the BRAF-MEK1 heterotetramer would
be favored over the MEK1-MEK1 homodimer. Thus, which pro-
tein MEK1 is associated with will depend on the cellular context,
including the relative concentrations and affinities of potential
binding partners. As BRAF is found in excess of immunode-
pleted MEK1 (Figure S1C), it is not surprising that MEK1 is
largely bound to BRAF in cell lines with low levels of basal
pMEK.
To confirm the physiological relevance of the BRAFKD-MEK1
crystal structure, we generated mutations targeting the hetero-
dimer interface (Figure 3A). Immunoprecipitation of transiently
transfected BRAF from BRAF null cells (HEC1A BRAF/) dem-
onstrates that interface mutations either in the N-terminal lobe
(R462E) or in the C-terminal lobe (I617R) of BRAF weaken bind-
ing to MEK1 (Figure 3B). Furthermore, the R462E substitution in
the P loop of BRAF enhances CRAF phosphorylation on S338
(Figure 3B), a known indicator of CRAF activity (Hu et al., 2013;
Mason et al., 1999) similar to assessments of nonactivating mu-
tations in the BRAF P loop (Wan et al., 2004). In contrast, the
BRAF I617R mutation alone completely disrupts binding to
MEK1 and does not enhance CRAF phosphorylation on S338.
While the structural rationale for the defect in MEK1 binding is
clear, the rationale for loss of CRAF transactivation is not
apparent. Complementary interface mutations in MEK1 also
weaken or abolish BRAF binding as revealed by BRAF-MEK1
protein-protein interaction assays (Figure 3C). Further, MEK1
variants with interface mutations result in diminished ERK phos-
phorylation (Figure 3D), suggesting that association with BRAF is
a prerequisite for MEK1 phosphorylation and subsequent ERK
phosphorylation. In sum, these data establish that the BRAF-
MEK1 interface observed in the crystal structure is functionally
relevant.
Oncogenic P Loop Mutations in BRAF Weaken the
BRAF-MEK1 Dimer and Enhance Pathway Activation
Activating, partially activating, and inactivating oncogenic
BRAF mutations occur in the vicinity of the BRAF-AS and the
BRAF-BRAF or BRAF-MEK1 interfaces (Figure S3A). While it
has been reported that the nonactivating BRAF P-loop muta-
tions require dimerization with CRAF to drive CRAF activation
(Freeman et al., 2013; Garnett et al., 2005; Wan et al., 2004), it.
A B
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Figure 4. Oncogenic Mutations in BRAF
P-Loop Have Decreased Affinity to MEK1
(A) MEK1 (pink) interacts with BRAF (cyan) P-loop
including formation of salt bridge between R462
from BRAF and E138 from MEK1. BRAF residues
465–469 are disordered but are expected to be in
close proximity to N lobe ofMEK1 (dotted line). The
approximate location of residues in the BRAF
glycine rich P-loop that are subject to inactivating
or partially activating mutations are indicated by
orange spheres.
(B) Pull-down (PD) of indicated recombinant full-
length Flag-BRAF variants with GST-MEK1 (top)
and coIP of Flag-BRAF variants with endogenous
CRAF in HEC1A BRAF/ (bottom).
(C) HEC1A BRAF/ cells were transfected with
vectors expressing the indicated BRAF for 24 hr.
Cell lysates were analyzed by SDS-PAGE followed
by immunoblotting. Levels of pMEK1/2 were
analyzed after a short exposure (short) and long
exposure (long).
(D) Recombinant protein PD of Flag-tagged BRAF
variants with increasing concentrations of MEK1
(0, 5, 10, 50, and 100 nM) followed by immunoblot.
Control immunoblots demonstrating the maximum
signal obtained from each concentration of MEK1
(top, left) and demonstrating nonspecific capture
of MEK1 in the absence of BRAF (top, right).
Numbers below each immunoblot represent the
ratio of MEK1 to BRAF based on relative intensities
of the bands from the immunoblots.
See also Figure S3.
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ization as the P-loop is on the opposite face of BRAF from the
dimerization interface. Although the BRAF P-loop is partially
disordered and any interactions it might make with the MEK1
activation loop during phosphorylation may be affected by the
presence of G-573 in our structure, it lies in close proximity to
a BRAFKD-MEK1 salt bridge at the dimer interface (BRAF
R462 and MEK1 E138; Figure 4A). As described above, overex-
pression of BRAFR462E in the HEC1A BRAF/ cell line resulted
in increased CRAF-Ser338 phosphorylation (pCRAF-S338),
enhanced pMEK levels, and reduced interaction with MEK1
(Figure 3B). Similarly, the oncogenic P loop BRAF variants
G464V, G464E, or G466V exhibit reduced MEK1 binding and
enhanced CRAF binding (Figure 4B). Overexpression of these
mutants in the HEC1A BRAF/ cell line enhances CRAF medi-
ated MEK1 activation, as indicated by pMEK and pCRAF-S338
levels (Figure 4C). To test whether BRAFP loop mutations directly
exhibit weakened affinity for MEK1, we assessed binding of
BRAFWT and BRAFP loop mutant proteins to MEK1 in pull-
down assays. As seen in Figure 4D, recombinant BRAFP-loop
mutants—including BRAFR462E, which forms a direct salt bridge
to MEK-E138 in our structure—exhibit weakened binding to
MEK1 compared to BRAFWT. While G464V and G464E have
reduced enzymatic activity but similar Km(ATP) compared to
BRAFWT, BRAF G466V/E mutants are catalytically inactive (Fig-
ure S3B and Figure S3C). Therefore, oncogenic mutations
within the P loop of BRAF function in a kinase-independent
manner by detrimentally affecting MEK1 binding to BRAF and
enhancing CRAF mediated signaling resulting in elevated
pMEK levels in cells.CaThe BRAF V600E-K507 Salt Bridge Renders BRAF
Kinase Activity Dimer Independent
BRAF activity is known to be dependent on dimerization and all
structures of BRAFKD known to date are dimeric (Figure S4A).
The commonly mutated residue V600 in the BRAF-AS lies in
close proximity to K507 in the aC helix of BRAFKD (Wan et al.,
2004) such that a V600E mutation could form favorable electro-
static interactions with K507. Structures of ATP bound or apo
BRAFKD-V600E are unavailable; however, our BRAF-MEK1
structure reveals similar positioning for V600 in the absence of
any bound inhibitor (Figure 5A). Consistent with published re-
ports, we find that BRAFWT catalytic activity requires BRAF
dimerization, while BRAFV600E catalytic activity remains insensi-
tive to this regulatory process (Figure S4B) (Holderfield et al.,
2013). Both the BRAF-MEK1 structure as well as the structure
of BRAFV600E bound to the inhibitor GDC-0879 display an active
conformation of the aC helix and AS (Figure 5A and Figure 5B). In
the context of BRAFV600E mutation, this conformation likely per-
sists even in the absence of dimerization due to formation of a
salt bridge between the negatively charged side chain of E600
with K507 in the aC helix in the BRAFKD (Figure 5B). Accordingly,
the charge-reversal mutation of K507 to glutamate, expected to
disrupt this salt bridge, renders BRAFV600E, K507E activity depen-
dent on dimerization (Figure 5C). The KD for ATP of BRAF
WT and
the dimer defective BRAFR509H is similar (Figure S4C), showing
that BRAF dimerization is not required for ATP or MEK1 binding
but is necessary for catalytic activity. Thus, the V600E mutation
renders BRAF constitutively active by stabilizing active confor-
mations of BRAF independent of RAS induced dimerization
with CRAF or BRAF.ncer Cell 26, 402–413, September 8, 2014 ª2014 Elsevier Inc. 407
A B C
Figure 5. Activating Mutation V600E Renders BRAF Kinase Activity Independent of Dimerization
(A) BRAF, both in a complex with MEK1 (left) and in a complex with GDC-0879 (right) adopts an active conformation in both BRAF aC helix and AS.
(B) Electron density (2Fo-Fc map, contoured at 1s) for the E600-K507 salt bridge in the BRAFV600E structure.
(C) HEC1A BRAF/ cells were transfected with vectors expressing the indicated BRAF for 24 hr. Cell lysates were analyzed by SDS-PAGE followed by
immunoblotting. Levels of pMEK1/2 were analyzed after a short exposure (short) and long exposure (long).
See also Figure S4.
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Kinase-Independent Role for BRAF in MAPK SignalingBRAF Inhibitors Can Enrich or Disrupt a
BRAF-MEK1 Complex
Since the BRAF-MEK1 complex is enriched in BRAFWT and
KRASMT cell lines where paradoxical activation with BRAF inhib-
itors is observed, we investigated the pharmacological effects of
BRAF inhibitors on complex formation. The subtle variations in
the conformation of BRAF observed in cocrystal structures
(Tsai et al., 2008; Wan et al., 2004; Wenglowsky et al., 2011) indi-
cate that BRAF is a dynamic protein that adopts different con-
formations depending on the nature of the bound inhibitor
(Figure S5A). Type I BRAF inhibitors that stabilize the aC helix
in an ‘‘active-like’’ conformation can induce priming of the
MAPK pathway in BRAFWT and KRASMT tumor lines through
enhanced BRAF-CRAF dimerization (Hatzivassiliou et al.,
2010). Comparing ‘‘active-like’’ (current work) and ‘‘inactive’’
BRAFKD structures (Bollag et al., 2010; Tsai et al., 2008; Wen-
glowsky et al., 2011) (Figure 6A), we predicted that BRAF inhib-
itors such as vemurafenib, PLX4720, or AR004549 that shift the
BRAF aC helix toward an inactive conformation would weaken
MEK1 binding, while BRAF inhibitors such as GDC-0879 that
favor the active orientation of the aC helix as well as the
extended conformation of the BRAF-AS (Figure 6A; Figure S5A)
would stabilize the BRAF-MEK1 complex. Indeed, GDC-0879
promotes binding of BRAFKD to MEK1 in the presence of ATP
or ACP in our in vitro biochemical assays, whereas vemurafenib
decreases it (Figure 6B; Figure S5B). In HCT116 (KRASMT) cells,
the RAF inhibitor GDC-0879 primes the pathway as observed
with elevated pMEK levels at the lowest concentration tested
but then enriches the BRAF-MEK1 complex while dampening
pMEK levels at the higher concentrations (Figure 6C). In contrast,
vemurafenib destabilizes the BRAF-MEK1 complex, resulting in
enhanced pathway activation and elevated pMEK levels (Fig-
ure 6C). Although vemurafenib does not substantially induce
BRAF-CRAF dimerization (Hatzivassiliou et al., 2010), the disso-
ciation of MEK1 from BRAF likely contributes to the priming
observed with inhibitors that stabilize inactive conformations of408 Cancer Cell 26, 402–413, September 8, 2014 ª2014 Elsevier IncBRAF, similar to what we have observed with the BRAFP-loop
mutant proteins. As expected, pathway priming by vemurafenib
is not seen in A375 cells (BRAFV600E) (Figure 6D) where BRAF-
MEK1 complexes are absent and the constitutively active kinase
is inhibited. Vemurafenib also has little effect on pMEK levels or
enrichment of RAF-MEK1 complexes in the BRAFP-loop cell line
MDA-MB-231 (Figure S5C) as the pathway is already primed
(BRAFP-loop and CRAF are constitutively dimerized and CRAF
is activated). In contrast, GDC-0879 effectively inhibits pMEK
levels in a dose-dependent manner in A375 tumor lines (Fig-
ure 6D) and in tumor lines such as MDA-MB-231 and H1666
that harbor BRAF P-loop mutations with concomitant enrich-
ment of RAF-MEK1 complexes (Figure 6E). This effect is due to
the ability of GDC-0879 to stabilize the active conformation of
BRAF preferred for binding to MEK1. In the absence of a struc-
ture of a BRAF P-loop mutant protein, it is difficult to predict
what specific conformation the protein adopts, but given the dy-
namic nature of the P loop in BRAF and other protein kinases
(Huse and Kuriyan, 2002; Patel and Doerksen, 2010), it is likely
that mutations in the BRAF P-loop impact the conformational
dynamics of the BRAF kinase domain, which would be expected
to impact interaction with MEK1. Thus, the mechanism of
action of GDC-0879 is 2-fold in that it not only inhibits BRAFV600E
enzymatic activity but also sequesters a dormant RAF-MEK1
complex in cells through stabilization of the active BRAF
conformation.
DISCUSSION
BRAF and MEK1 form a high affinity complex that is sensitive to
MEK1 phosphorylation and to the active conformation of the
BRAF kinase domain but is independent of BRAF dimerization.
Further, complexes of BRAF and MEK1 exist in the cytosol of
BRAFWT and KRASMT cells awaiting additional signaling cues
for RAS-mediated RAF dimerization and MEK phosphorylation
resulting in dissociation of the BRAF-MEK1 complex. As the.
AB C
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Figure 6. Different Classes of BRAF Inhibi-
tors Have Distinct Effects on the BRAF-
MEK1 Protein Complex
(A) BRAF inhibitors that exhibit a binding mode
similar to vemurafenib stabilize an inactive
conformation of the aC helix in BRAFKD (yellow,
orange; PDB code 3TV6, chain B) (Wenglowsky
et al., 2011) and favor conformations of the AS
incompatible with MEK1 binding.
(B) BRAFKD-MEK1 complexes are detected by
hTRF in vitro in the presence of 10 mM of the indi-
cated BRAF inhibitors (vemurafenib, GDC-0879),
MEK inhibitor (G-573), or DMSO; 100 mM of ATP
was included in all conditions except for the no ATP
control as indicated. Data were normalized to the
no ATP control, which was defined as 100% BRAF
bound. Error bars represent standard deviations.
(C) IP of MEK1 followed by western blot analysis of
HCT116 cells treated with 0.1 mM, 1 mM, and 10 mM
of the indicated compound for 1 hr.
(D and E) Immunoblots of WCL or IP of MEK1 of
A375 (D), MDA-MB-231, or NCI-H1666 (E) cells
treated with 0.1 mM, 1 mM, and 10 mM of the indi-
cated compound for 1 hr.
See also Figure S5.
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Kinase-Independent Role for BRAF in MAPK SignalingN-terminal domain of the full-length RAF acts as an autoregula-
tory domain preventing RAF dimerization and membrane locali-
zation (Chong andGuan, 2003; Cutler et al., 1998; Terai andMat-
suda, 2006; Tran et al., 2005; Weber et al., 2001) and since the
full-length RAF resides as amonomer in the cytosol under resting
conditions (Nan et al., 2013), we propose that the cytosolic andCancer Cell 26, 402–413, Squiescent BRAF-MEK1 complex
observed in cells is likely a heterodimeric
complex with the N-terminal domain of
the full-length BRAF preventing RAF
dimerization until the pathway is stimu-
lated (see model in Figure 7). Pathway
activation would result in BRAF-CRAF
dimerization and formation of a transient,
signaling competent heterotetrameric
RAF-MEK1 complex that can rapidly
phosphorylate MEK1 in cis. This heterote-
trameric complex is captured in our
BRAF-MEK1 crystal structure in the pres-
ence of the MEK inhibitor G-573. Once
MEK1 is phosphorylated, the RAF-MEK1
heterotetrameric complex is destabilized
and phosphorylated MEK1 is available to
phosphorylate the terminal kinase ERK in
the signaling pathway. Over time as
pathway feedback is induced and pMEK
levels decrease, the BRAF-MEK1 com-
plex is reestablished.
Our structural studies have generated
insights on the diverse mechanisms of
activating and nonactivating BRAF muta-
tions. The BRAFV600E mutation activates
the pathway by favoring a constitutively
active conformation independent ofBRAF dimerization, whereas nonactivating BRAFP-loopmutations
weaken the BRAF-MEK1 interface and enhance BRAF-CRAF
dimerization (see model in Figure 7). Hence, the presence of a
preformedBRAF-MEK1 complex in cells suggests that substrate
recognition (i.e., RAF recognition of its substrate MEK1) is not a


























Figure 7. Model Depicting MAPK Pathway Activation in Different Genetic Contexts
In the context of BRAFWT, the quiescent, dimeric BRAF-MEK complex resides in the cytosol awaiting RAS-mediated pathway activation to translocate to the
membrane and dimerize with another RAF protomer, thereby forming a transient and active heterotetrameric RAF-MEK complex (left). In contrast, BRAFV600E
phosphorylates MEK independent of BRAF dimerization leading to elevated levels of phosphorylated MEK, thus disfavoring a stable BRAF-MEK complex
(middle). Inactivating mutations in BRAF (BRAFInactive) such as the P loop mutation BRAFG466V exhibit weakened interaction with MEK, which results in increased
BRAF-CRAF dimerization, CRAF activation, and enhanced levels of phosphorylated MEK (right). This model illustrates that substrate availability (in this case
BRAF recognition of its substrate MEK) is not the rate-limiting step in BRAF-MEK pathway activation, but rather BRAF and/or CRAF dimerization is.
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Kinase-Independent Role for BRAF in MAPK SignalingBRAF and CRAF dimerization is. Indeed, oncogenic mutations in
BRAF either bypass the requirement for dimerization completely
(i.e., BRAFV600E), constitutively dimerize with CRAF (i.e., BRAFP-
loop mutations), or form constitutive BRAF homodimers through
deletion of the BRAFN-terminal negative regulatory domain (Sie-
vert et al., 2013).
As RAF dimerization is a key step in pathway activation, it is
not surprising that BRAF and CRAF heterodimerization and
MEK1 activation is tightly regulated and dependent on multiple
factors including RAF phosphorylation and interaction with 14-
3-3 (Garnett et al., 2005; Ritt et al., 2010; Rushworth et al.,
2006). BRAF and CRAF have distinct functions with respect
to MEK1 activation, leading to a recent model in which BRAF
functions as the ‘‘activator’’ of the CRAF ‘‘receiver’’ kinase
through a dimerization-dependent mechanism that drives
CRAF autophosphorylation (Hu et al., 2013). In this model,
CRAF association with MEK occurs only after membrane local-
ization and dimerization of BRAF and CRAF. This agrees well
with our observations that cell lines with low basal pMEK levels
are enriched with high BRAF-MEK1 complexes and less so
with CRAF-MEK1. As the relative stoichiometry of BRAF and
CRAF can affect MAPK signaling output and since the MEK
interaction with CRAF drives CRAF activation (Hu et al.,
2013; Leicht et al., 2013), our data suggest that the presence
of a BRAF-MEK1 complex modulates flux through the MAPK
pathway. Accordingly, mutations in the BRAFP-loop, which
exhibit weakened interaction with MEK1 and enhanced dimer-
ization with CRAF, likely position BRAFP-loop to function as410 Cancer Cell 26, 402–413, September 8, 2014 ª2014 Elsevier Incan ‘‘activator’’ of CRAF through a dimerization-dependent
manner.
Regulation of BRAF-CRAF dimerization through interaction
with 14-3-3 is yet another mechanism to control pathway
signaling. Mutation of CRAF-S621 or BRAF-S729 (residues
recognized by 14-3-3) to alanine modulates binding of CRAF
to BRAF and diminishes CRAF kinase activity even in the
context of oncogenic BRAFP-loop mutants, suggesting that mu-
tation of the BRAFP-loop alone is not sufficient to activate the
pathway (Garnett et al., 2005; Ritt et al., 2010; Rushworth
et al., 2006). Hence, BRAF P-loop mutations enhance B and
CRAF heterodimers in a 14-3-3-dependent fashion, resulting in
enhanced CRAF activation. Interestingly, we were able to isolate
MEK1-BRAF-14-3-3 complexes, indicating that the BRAF-
MEK1 complex is stable even in the presence of the 14-3-3
protein (data not shown). Further studies are needed to under-
stand how scaffolding and chaperone proteins affect MAPK
pathway flux in the context of regulating BRAF-MEK1 complex
formation.
Our data also shed light on existing models of KSR as a scaf-
folding protein in canonical MAPK signaling. As our studies show
that the BRAFKD-MEK1 is a high affinity complex, local concen-
tration and cellular stoichiometry of KSR may be a key determi-
nant for displacing BRAF from MEK1. Furthermore, KSR may be
more competent as a RAF activating protein, where it can
enhance MAPK signaling by forming a dimer with BRAF or
CRAF (McKay et al., 2011; Michaud et al., 1997; Rajakulendran
et al., 2009) rather than serving to recruit MEK to BRAF-CRAF.
Cancer Cell
Kinase-Independent Role for BRAF in MAPK Signalingcomplexes activated by RAS on the plasma membrane (Morri-
son, 2001; Mu¨ller et al., 2001).
Understanding different molecular mechanisms governing
BRAF-mediated pathway activation may aid in developingmuta-
tion-appropriate therapeutic strategies. Type I ATP competitive
BRAF inhibitors that position BRAF in an active conformation
and enrich RAF-MEK1 complexes can antagonize the MAPK
pathway by inhibiting both kinase-dependent and kinase-inde-
pendent functions of BRAF. Sequestering signaling incompetent
RAF-MEK1 complexes in cells with BRAF inhibitors may have
particular utility in settings where kinase inactivating BRAFmuta-
tions are the drivers of pathway activity. Importantly, we show
that ATP-competitive BRAF inhibitors can affect both kinase ac-
tivity and the propensity of BRAF to engage in protein-protein in-
teractions. In particular, the BRAF activation segment, aC helix
and the P-loop exhibit conformational variability in the presence
of inhibitors, oncogenic mutations, or protein binding partners.
This conformational plasticity of BRAF alters pathway signaling
analogous to the signaling mechanisms associated with G pro-
tein coupled receptors, nuclear hormone receptors, and small
GTPase signaling proteins (Kobilka and Deupi, 2007; Nagy and
Schwabe, 2004; Vetter and Wittinghofer, 2001). As with these
proteins, targeting kinases with ATP-competitive inhibitors that
stabilize active or inactive conformations of the enzyme can
not only block kinase activity directly but also elicit additional ef-
fects on pathway signaling due to altered protein-protein interac-
tions. In the case of MAPK signaling, the additional effects are
counterintuitive as enzymatic inhibitors can induce pathway acti-
vation by favoring BRAF-CRAF heterodimers (Hatzivassiliou
et al., 2010; Heidorn et al., 2010; Poulikakos et al., 2010) or
can block the pathway through both inhibition of enzymatic
activity and enrichment of a dormant kinase-substrate (RAF-
MEK1) protein complex as we have reported for both BRAF
and MEK inhibitors (Hatzivassiliou et al., 2013). For other ki-
nases, the effects will depend on the specifics of the signaling
pathways involved. Thus, the conformational dependence of
regulatory functions of proteins is an important factor for consid-
eration in the discovery and design of therapeutic inhibitors.
EXPERIMENTAL PROCEDURES
Additional procedures are described in the Supplemental Experimental
Procedures.
Antibodies, Reagents, and Cell Lines
Anti-BRAF and -RHO GDI were purchased from Santa Cruz Biotechnology.
Anti-CRAF was purchased from BD Biosciences. Anti-pMEK1/2, -MEK1,
-ERK1/2, -pERK1/2, -Ras, -Cadherin, and -pCRAFS338 were purchased
fromCell Signaling Technology. Anti-FLAG antibody and EGF were purchased
from Sigma-Aldrich. Mammalian BRAF cDNA expression constructs used in
this work were described previously (Hatzivassiliou et al., 2010) and generated
with the QuickChange site-directed mutagenesis kit (Agilent Technologies)
using BRAFWT as the template. G-573 and GDC-0879 were synthesized at
Genentech as described previously (Choo et al., 2010; Hansen et al., 2008).
Vemurafenib was synthesized as described in WO2007002325. PLX4720
was purchased from Active Biochem. Cells were obtained from the Genentech
cell line repository and were cultured according to ATCC specifications. The
HEC1A BRAF/ cell line has been described previously (Kim et al., 2004).
Biochemical Detection of RAF-MEK1 Protein Complexes
Biochemical BRAF-MEK1 homogeneous time-resolved fluorescence (hTRF)
based experiments and kinase assays were conducted as described previ-Caously (Hatzivassiliou et al., 2013). Detection of RAF-MEK1 complexes from
cells was performed by coimmunoprecipitation. Briefly, cells were lysed in
assay buffer (10 mM Tris [pH 7.4], 50 mM NaCl, 0.5% [v/v] NP-40, 1 mM
EDTA, 13 protease inhibitors, and 13 HALT phosphatase inhibitors). MEK1,
BRAF, or CRAF were immunoprecipitated from 1 mg of precleared cell lysate
with rabbit anti-MEK1 (Millipore No. 07-641), rabbit anti-BRAF (Sigma No.
A001328), or rabbit anti-CRAF (Millipore No. 07-396) overnight at 4C. Protein
A agarose beads (Thermo Scientific No. 53139) were used to capture the pro-
tein-antibody complex, followed by washes and the addition of SDS sample
buffer. Samples were boiled and analyzed by immunoblot.
Subcellular Fractionation
Cells were harvested in fractionation buffer (20 mM Tris [pH 7.4], 50 mM NaCl,
13 EDTA-free protease inhibitors, and 13HALT phosphatase inhibitors). After
incubation on ice for 20 min, cells were homogenized by shearing through a
27-gauge needle. The sample was centrifuged at 2,000 rpm for 10 min to sedi-
ment the nuclei. The supernatant was then spun at 14,000 rpm for 30 min at
4C to separate the sedimented membrane fraction from the soluble cytosolic
fraction. The membrane pellet was washed with 1 ml of fractionation buffer,
centrifuged at 14,000 rpm for 20 min at 4C, and resuspended in fractionation
buffer containing 1% NP-40. Fractions were analyzed by immunoblot.
Protein Production, Purification, and Crystallization of
BRAFKD-DNMEK1 and BRAFV600E
His-tagged human recombinant BRAFKD (insect cells) and. DNMEK1 (E. coli)
were purified by affinity, ion exchange and size exclusion chromatography.
BRAFKD and excess DNMEK were incubated at 4C, and the complex purified
by size exclusion chromatography. The tetramer-containing fractions were
pooled and concentrated to 16 mg/ml in a ‘‘complex buffer’’ (see Supple-
mental Experimental Procedures). The BRAFKD-DNMEK1 complex crystallized
in 2 ml hanging drops composed of equal amounts of protein at 16 mg/mL and
well solution of 12%–18% PEG 8000 and 0.1 M Tris (pH 8.5–8.8). Crystals ap-
peared after 3 weeks and grew to 100–200 mm in size in 5 weeks. Data were
collected at SSRL beamline 11-1. The structure was solved by molecular
replacement using PDB codes 1UWH and 2EQC as search models, revealing
two BRAFKD-MEK1 tetramers in the crystallographic asymmetric unit. Cycles
of building and refinement resulted in the final model. Structural figures were
created with Pymol. Crystals of BRAFKD bound to GDC-0879 were grown
and the structure solved as described in Supplemental Experimental
Procedures.
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